NTLA

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. Founded in 2014, Intellia focuses on developing potentially curative therapeutics using CRISPR/Cas9 gene-editing technology. The company's pipeline includes both in vivo and ex vivo programs aimed at treating a range of genetic diseases. Notably, its in vivo candidates, NTLA-2001 and NTLA-2002, target transthyretin amyloidosis and hereditary angioedema, respectively. Intellia collaborates with several organizations, including Regeneron and Novartis, to advance its therapeutic programs. The company is recognized for pioneering the first systemic in vivo CRISPR therapy administered to humans, marking a significant milestone in gene-editing therapeutics. ​WikipediaPitchBook+6Intellia Therapeutics+6Wikipedia+6Wikipedia+2GlobalData+2Investing.com+2IntelliATX Investor Relations+2Investing.com+2Wikipedia+2PitchBook

Over the past 52 weeks, NTLA's stock has reached a high of $28.18 and a low of $5.90. ​MarketWatch+8INDmoney+8Robinhood+8

Analyst sentiment for Intellia Therapeutics is generally positive. According to MarketBeat, among 20 analysts:​MarketBeat

• 1 has issued a Sell rating
• 6 have given Hold ratings
• 12 have assigned Buy ratings
• 1 has provided a Strong Buy rating​StockInvest+1Yahoo Finance+1PitchBook+4MarketBeat+4Barchart.com+4

This distribution results in a consensus rating of "Moderate Buy." ​MarketBeat+1Zacks+1

Subscribe to our API. See Strong Buy and Sell Signals the Day after They Occur!